The synthetic LXR agonist T0901317 restored LXR-mediated ABCA1 expression in a cell-line transfected with the mutant LXR, suggesting that pharmacological activation of LXRs could be beneficial in progressive MS. Here, ABCA1 is linked to myeloid sarcoma.